Tim Bancroft

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 14

Top Topics

Allogeneic Hematopoietic Stem Cell Transplantation

Health Insurance

Ejection Fraction

Cross Sectional

Top Venues

Journal of comparative effectiveness research

Advances in therapy

Neurourology and urodynamics

This page only lists publications with an associated author ORCID identifier.

Publications

Benjamin Chastek, Adam Carrera, Christina Landis, Daniel Snyder, Laleh Abedinzadeh, Tim Bancroft, Jeffrey Nesheim, Michael J Kennelly, David Staskin
Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study. Neurourology and urodynamics 43 (7) (2024)
Benjamin Chastek, Adam Carrera, Christina Landis, Daniel Snyder, Laleh Abedinzadeh, Tim Bancroft, Jeffrey Nesheim, Michael J Kennelly, David Staskin
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis. Advances in therapy 41 (5) (2024)
Benjamin Chastek, Adam Carrera, Christina Landis, Daniel Snyder, Laleh Abedinzadeh, Tim Bancroft, Jeffrey Nesheim, Michael J Kennelly, David Staskin
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis. Advances in therapy (2024)
Benjamin Chastek, Adam Carrera, Christina Landis, Daniel Snyder, Laleh Abedinzadeh, Tim Bancroft, Jeffrey Nesheim, Michael J Kennelly, David Staskin
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis. Advances in therapy 41 (5) (2024)
Benjamin Chastek, Adam Carrera, Christina Landis, Daniel Snyder, Laleh Abedinzadeh, Tim Bancroft, Jeffrey Nesheim, Michael J Kennelly, David Staskin
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis. Advances in therapy 41 (5) (2024)
Benjamin Chastek, Adam Carrera, Christina Landis, Daniel Snyder, Laleh Abedinzadeh, Tim Bancroft, Jeffrey Nesheim, Michael J Kennelly, David Staskin
Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study. Neurourology and urodynamics 43 (7) (2024)
Benjamin Chastek, Adam Carrera, Christina Landis, Daniel Snyder, Laleh Abedinzadeh, Tim Bancroft, Jeffrey Nesheim, Michael J Kennelly, David Staskin
Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study. Neurourology and urodynamics (2024)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)